Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics
Highlights The major highlights of this study are as follows: Key upregulated hub kinases and coding genes in GBM are found to be targets of SUMO2 conjugation. SUMO2 is significantly expressed in adult primary and recurrent GBMs as well as in pediatric GBM tumours. Orthotropic xenografts from adult...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-021-02279-y |
| _version_ | 1818843152660824064 |
|---|---|
| author | Aswani P. Krishna Sebastian John Puja Laxmanrao Shinde Rashmi Mishra |
| author_facet | Aswani P. Krishna Sebastian John Puja Laxmanrao Shinde Rashmi Mishra |
| author_sort | Aswani P. Krishna |
| collection | DOAJ |
| description | Highlights The major highlights of this study are as follows: Key upregulated hub kinases and coding genes in GBM are found to be targets of SUMO2 conjugation. SUMO2 is significantly expressed in adult primary and recurrent GBMs as well as in pediatric GBM tumours. Orthotropic xenografts from adult and pediatric GBMs confirm high expression of SUMO2 in GBM tumour samples. SUMO2 is significantly associated with patient survival plot and pan-cancer cell fitness. Rationale design of SUMO2 inhibitors or search for its transcriptional inhibitors is urgently required through industry-academia collaboration for an anti-GBM and potentially pan-cancer therapeutics. |
| first_indexed | 2024-12-19T04:53:20Z |
| format | Article |
| id | doaj.art-e9aaad9cbeb44e689f1b57b7caf29955 |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-12-19T04:53:20Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-e9aaad9cbeb44e689f1b57b7caf299552022-12-21T20:35:17ZengBMCCancer Cell International1475-28672021-10-0121111610.1186/s12935-021-02279-yProteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeuticsAswani P. Krishna0Sebastian John1Puja Laxmanrao Shinde2Rashmi Mishra3Brain and Cerebro-Vascular Mechanobiology Research, Laboratory of Translational Mechanobiology, Department of Neurobiology, Rajiv Gandhi Centre for BiotechnologyBrain and Cerebro-Vascular Mechanobiology Research, Laboratory of Translational Mechanobiology, Department of Neurobiology, Rajiv Gandhi Centre for BiotechnologyBrain and Cerebro-Vascular Mechanobiology Research, Laboratory of Translational Mechanobiology, Department of Neurobiology, Rajiv Gandhi Centre for BiotechnologyBrain and Cerebro-Vascular Mechanobiology Research, Laboratory of Translational Mechanobiology, Department of Neurobiology, Rajiv Gandhi Centre for BiotechnologyHighlights The major highlights of this study are as follows: Key upregulated hub kinases and coding genes in GBM are found to be targets of SUMO2 conjugation. SUMO2 is significantly expressed in adult primary and recurrent GBMs as well as in pediatric GBM tumours. Orthotropic xenografts from adult and pediatric GBMs confirm high expression of SUMO2 in GBM tumour samples. SUMO2 is significantly associated with patient survival plot and pan-cancer cell fitness. Rationale design of SUMO2 inhibitors or search for its transcriptional inhibitors is urgently required through industry-academia collaboration for an anti-GBM and potentially pan-cancer therapeutics.https://doi.org/10.1186/s12935-021-02279-yGlioblastoma multiformeCancer drug target discoverySUMO2Kinases and cancerTCGA |
| spellingShingle | Aswani P. Krishna Sebastian John Puja Laxmanrao Shinde Rashmi Mishra Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics Cancer Cell International Glioblastoma multiforme Cancer drug target discovery SUMO2 Kinases and cancer TCGA |
| title | Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics |
| title_full | Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics |
| title_fullStr | Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics |
| title_full_unstemmed | Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics |
| title_short | Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics |
| title_sort | proteo transcriptomics meta analysis identifies sumo2 as a promising target in glioblastoma multiforme therapeutics |
| topic | Glioblastoma multiforme Cancer drug target discovery SUMO2 Kinases and cancer TCGA |
| url | https://doi.org/10.1186/s12935-021-02279-y |
| work_keys_str_mv | AT aswanipkrishna proteotranscriptomicsmetaanalysisidentifiessumo2asapromisingtargetinglioblastomamultiformetherapeutics AT sebastianjohn proteotranscriptomicsmetaanalysisidentifiessumo2asapromisingtargetinglioblastomamultiformetherapeutics AT pujalaxmanraoshinde proteotranscriptomicsmetaanalysisidentifiessumo2asapromisingtargetinglioblastomamultiformetherapeutics AT rashmimishra proteotranscriptomicsmetaanalysisidentifiessumo2asapromisingtargetinglioblastomamultiformetherapeutics |